



Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

J.B.Chemicals reports robust profits in Q3

Mumbai, January 13, 2011: J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its unaudited standalone financial results for the quarter ended December 2010. The highlights of these results are as under:

HIGH LIGHTS: Q3

- **Net Sales at Rs. 216.68 crores; Up 9.39% Y-o-Y.**
- **EBIDTA at Rs. 53.53 crores; Up 19.92% Y-o-Y**
- **PAT at Rs. 38.12 crores; Up 28.95 % Y-o-Y.**
- **EPS–Rs.4.51 (Diluted); Up 28.49 % Y-o-Y.**

HIGH LIGHTS: For 9 months

- **Net Sales at Rs. 608.69 crores; Up 20.69 % Y-o-Y.**
- **EBIDTA at Rs. 145.57 crores; Up 28.85 % Y-o-Y.**
- **PAT at Rs. 103.43 crores; Up 39.73 % Y-o-Y.**
- **EPS- Rs.12.23 (Diluted); Up 39.29 % Y-o-Y.**

During the quarter, the net sales achieved growth of 9.39%. The growth achieved by formulations exports in US dollar terms was 5%, while the domestic formulations business continued to achieve good growth during the quarter. The continued efficiency improvement and cost containment across the business helped achieve better profits.

The company's increased concentration on formulations exports has yielded positive results that are reflected in 21% growth achieved for nine months ended December, 2010.

The company continues to aggressively focus on domestic formulations business. The total medical representative strength as on December 2010 has increased to 690. The growth of focused brands has been encouraging

During the current quarter, the company filed international patent application for novel Nicotine formulation that holds good promise for the company's exports business. During the quarter, the company received approval from US FDA to its ANDA for 25 mg. and 50 mg. delayed release tablets of Diclofenac Sodium (Non-Steroidal Anti-inflammatory Drug). This approval significantly improves business prospects for this product in US as the company already markets 75 mg. formulation of the said drug.

The leading South African pharmaceutical company and the Australian OTC major have expanded their business arrangement with the company for purchase of lozenges. The company will also commence supplies of lozenges to a UK multinational during the current quarter consequent to successful social accountability audit of the company's facility. The company has also entered into contract for supply of different forms of eye drops, which is scheduled to commence next year.

The investment of Rs. 40 crores being made by the company during the year in manpower, new marketing & R&D initiatives and modernization of Kadaiya (Daman) and Panoli (Gujarat) facilities will all help achieve future growth.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and API's. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine and the other CIS countries. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMFs and ANDAs. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta
Company Secretary- General Manager
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 3045 1311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.